EU Pharma Reset Enters Make-or-Break Phase
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
$2995
In the EU, 2025–26 has been an exceptionally busy time for pharmaceutical-related reforms. Political agreement on the pharma reform package in late 2025, coupled with progress on finalizing the Critical Medicines Act (CMA) and the Biotech Act in early 2026, mean that many of the uncertainties over policy direction have now been resolved. As such, the EU is starting to move into a make-or-break period of reform implementation.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
See what our customers are saying
Related reports
View more Product Type reports
New
New
New